MX356671B - Métodos para inhibir fucosilación de proteína in vivo utilizando análogos de fucosa. - Google Patents

Métodos para inhibir fucosilación de proteína in vivo utilizando análogos de fucosa.

Info

Publication number
MX356671B
MX356671B MX2013001303A MX2013001303A MX356671B MX 356671 B MX356671 B MX 356671B MX 2013001303 A MX2013001303 A MX 2013001303A MX 2013001303 A MX2013001303 A MX 2013001303A MX 356671 B MX356671 B MX 356671B
Authority
MX
Mexico
Prior art keywords
vivo
inhibition
methods
protein fucosylation
fucose analogs
Prior art date
Application number
MX2013001303A
Other languages
English (en)
Other versions
MX2013001303A (es
Inventor
Dennis Benjamin
Peter Senter
Stephen Alley
Original Assignee
Seattle Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Genetics Inc filed Critical Seattle Genetics Inc
Publication of MX2013001303A publication Critical patent/MX2013001303A/es
Publication of MX356671B publication Critical patent/MX356671B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La invención proporciona métodos y composiciones para inhibir la fucosilación de proteínas, incluyendo anticuerpos, in vivo por administración de un análogo de fucosa.
MX2013001303A 2010-08-05 2011-08-05 Métodos para inhibir fucosilación de proteína in vivo utilizando análogos de fucosa. MX356671B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37111610P 2010-08-05 2010-08-05
PCT/US2011/046857 WO2012019165A2 (en) 2010-08-05 2011-08-05 Methods of inhibition of protein fucosylation in vivo using fucose analogs

Publications (2)

Publication Number Publication Date
MX2013001303A MX2013001303A (es) 2014-07-24
MX356671B true MX356671B (es) 2018-06-08

Family

ID=45560106

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013001303A MX356671B (es) 2010-08-05 2011-08-05 Métodos para inhibir fucosilación de proteína in vivo utilizando análogos de fucosa.

Country Status (21)

Country Link
US (4) US9504702B2 (es)
EP (2) EP3513794A3 (es)
JP (4) JP5918235B2 (es)
KR (2) KR20190022884A (es)
CN (2) CN107007615A (es)
AU (3) AU2011285490B2 (es)
CA (1) CA2803388C (es)
CY (1) CY1121419T1 (es)
DK (1) DK2608796T3 (es)
ES (1) ES2711622T3 (es)
HU (1) HUE043370T2 (es)
IL (2) IL224487A (es)
MX (1) MX356671B (es)
NZ (1) NZ606250A (es)
PL (1) PL2608796T3 (es)
PT (1) PT2608796T (es)
RU (2) RU2625768C2 (es)
SI (1) SI2608796T1 (es)
TR (1) TR201902439T4 (es)
WO (1) WO2012019165A2 (es)
ZA (1) ZA201300653B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102076865B (zh) 2008-05-02 2016-03-16 西雅图基因公司 用于制造核心岩藻糖基化降低的抗体和抗体衍生物的方法和组合物
MX356671B (es) 2010-08-05 2018-06-08 Seattle Genetics Inc Métodos para inhibir fucosilación de proteína in vivo utilizando análogos de fucosa.
CA2882725C (en) * 2012-08-23 2021-03-09 Regents Of The University Of Minnesota Treatment of sickle cell disease and inflammatory conditions
EP2958905B1 (en) 2013-02-22 2017-03-29 Amgen Inc. Carbohydrate phosphonate derivatives as modulators of glycosylation
CN106699886A (zh) * 2015-07-13 2017-05-24 西藏海思科药业集团股份有限公司 抗体依赖性细胞介导的细胞毒性(adcc)增强的奥法木抗体
SG10202005298RA (en) * 2015-12-04 2020-07-29 Seattle Genetics Inc Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor
JP6882339B2 (ja) * 2016-05-10 2021-06-02 アレス トレーディング ソシエテ アノニム ペルアセチルガラクトースを使った組換えタンパク質のタンパク質ガラクトシル化プロファイルを改変する方法
JP2018002666A (ja) * 2016-07-04 2018-01-11 国立研究開発法人理化学研究所 フコース類似体と糖を検出する方法
AU2018282225B2 (en) * 2017-06-07 2024-06-13 Seagen Inc. T cells with reduced surface fucosylation and methods of making and using the same
KR20200092328A (ko) 2017-12-01 2020-08-03 화이자 인코포레이티드 항-cxcr5 항체 및 그의 조성물 및 용도
CA3094756A1 (en) 2018-03-29 2019-10-03 Pfizer Inc. Lfa3 variants and compositions and uses thereof
KR20210057053A (ko) 2018-08-23 2021-05-20 씨젠 인크. 항-tigit 항체
US20220062315A1 (en) * 2018-12-27 2022-03-03 Keio University Anti-human norovirus agent
US20230022796A1 (en) * 2019-12-19 2023-01-26 Merck Patent Gmbh Methods and compositions for modulating the glycosylation profile of proteins
IL272389A (en) 2020-01-30 2021-08-31 Yeda Res & Dev Kits containing antibodies to PD-L1 and their uses in therapy
JP2023528400A (ja) * 2020-06-03 2023-07-04 サイモン フレイザー ユニヴァーシティー タンパク質フコシル化の阻害剤及びその用途
CA3222409A1 (en) 2021-06-07 2022-12-15 Amgen Inc. Using fucosidase to control afucosylation level of glycosylated proteins
CN113413465B (zh) * 2021-06-15 2022-06-03 北京大学 岩藻糖基化抑制剂在抗癌导致炎症中的应用

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440780A (en) 1979-06-01 1984-04-03 Chevron Research Company Fungicidal 3-(N-acyl-N-arylamino)-and 3-(N-thionoacyl-N-arylamino)-gamma-butyrolactones and gamma-thiobutyrolactones
JPH0660189B2 (ja) 1986-01-22 1994-08-10 財団法人微生物化学研究会 ２，６−ジデオキシ−２−フルオロ−ｌ−タロピラノ−ス又はその誘導体とその製造法
FR2630914A1 (fr) 1988-05-04 1989-11-10 Hoechst Sa Laboratoires Nouveaux analogues du l-fucose, leur procede de preparation, application de ces analogues a la preparation de nouveaux glycals, anthracyclines obtenues a l'aide de ces glycals et utilisation desdites anthracyclines en tant que medicaments
KR100211417B1 (ko) 1990-11-30 1999-10-01 유충식 L-탈로피라노시드 유도체 및 그의 제조방법
US5461143A (en) 1991-03-18 1995-10-24 The Scripps Research Institute Oligosaccharide enzyme substrates and inhibitors: methods and compositions
US5210078A (en) * 1991-04-30 1993-05-11 The Biomembrane Institute Trifluoromethyl analogs of fucose and uses thereof
SK42594A3 (en) 1991-10-15 1994-10-05 Scripps Research Inst Method of production of fucosylated carbohydrates
EP0721956B1 (en) 1993-09-29 2000-08-02 Nissin Shokuhin Kabushiki Kaisha 21-substituted steroid compound
US5481143A (en) 1993-11-15 1996-01-02 Burdick; Brian K. Self starting brushless d.c. motor
FR2723947B1 (fr) 1994-08-31 1996-09-27 Adir Nouveaux composes tetrahydropyraniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE19524515A1 (de) 1995-07-05 1997-01-09 Deutsches Krebsforsch Saccharid-Konjugate
US6713287B1 (en) 1995-10-24 2004-03-30 The Scripps Research Institute Enzymatic synthesis of L-fucose and L-fucose analogs
WO1998018805A2 (en) 1996-10-28 1998-05-07 Novartis Ag Sugar derivatives as sialyl lewis x mimetics
US5770407A (en) 1996-12-10 1998-06-23 The Scripps Research Institute Process for preparing nucleotide inhibitors of glycosyltransferases
JP4451933B2 (ja) * 1996-12-27 2010-04-14 住友化学株式会社 遺伝子操作による植物へのｐｐｏ阻害性除草剤耐性付与法
US6075134A (en) 1997-05-15 2000-06-13 The Regents Of The University Of California Glycoconjugates and methods
JPH1135593A (ja) 1997-07-18 1999-02-09 Daikin Ind Ltd ２−フルオロフコシル−ｎ−アロイルグルコサミン誘導体及びその中間物、並びにそれらの製造方法
US6670330B1 (en) 2000-05-01 2003-12-30 Theodore J. Lampidis Cancer chemotherapy with 2-deoxy-D-glucose
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7265084B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
JPWO2003085118A1 (ja) 2002-04-09 2005-08-11 協和醗酵工業株式会社 抗体組成物の製造方法
KR20050098244A (ko) 2003-01-10 2005-10-11 쓰레솔드 파마슈티컬스, 인코포레이티드 2-데옥시글루코오스를 사용한 암 치료 방법
EP2338333B1 (en) 2003-04-09 2017-09-06 ratiopharm GmbH Glycopegylation methods and proteins/peptides produced by the methods
EP1613261A4 (en) 2003-04-09 2011-01-26 Novo Nordisk As INTRA-CELLULAR FORMATION OF PEPTIDE CONJUGATES
US7332334B2 (en) 2003-04-18 2008-02-19 Oklahoma Medical Research Foundation Hematopoietic stem cells treated by in vitro fucosylation and methods of use
EP2228445A1 (en) 2003-06-18 2010-09-15 Chugai Seiyaku Kabushiki Kaisha Fucose Transporter
CA2542130A1 (en) 2003-10-09 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Cell genomically modified to produce polypeptides with an altered glycosylation pattern
CA2551181A1 (en) 2003-12-23 2005-07-07 Progen Industries Limited Glycosaminoglycan (gag) mimetics
DE102004032421A1 (de) 2004-07-05 2006-01-26 Bayer Cropscience Ag Phenylsubstituierte [1.2]-Oxazin-3,5-dion-und Dihydropyron-Derivate
US7393836B2 (en) 2004-07-06 2008-07-01 Boehringer Ingelheim International Gmbh D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
WO2006067847A1 (ja) 2004-12-22 2006-06-29 Chugai Seiyaku Kabushiki Kaisha フコーストランスポーターの機能が阻害された細胞を用いた抗体の作製方法
JP5122441B2 (ja) 2005-04-19 2013-01-16 シアトル ジェネティックス， インコーポレイテッド ヒト化抗ｃｄ７０結合剤およびその使用
PL1945665T3 (pl) 2005-10-21 2012-02-29 Genzyme Corp Leki oparte na przeciwciałach z ulepszoną aktywnością adcc
WO2007064448A2 (en) 2005-11-28 2007-06-07 Ramot At Tel Aviv University, Ltd. Cancer treatment using fts and 2-deoxyglucose
EP1976987B1 (en) 2005-12-21 2012-06-27 Viventia Biotechnologies Inc. Cancer-associated Scratch variant
WO2007081031A1 (ja) 2006-01-16 2007-07-19 Hokkaido University 糖転移酵素阻害剤
EP1987068B1 (en) 2006-02-10 2018-08-08 Life Technologies Corporation Oligosaccharide modification and labeling of proteins
CN101426508A (zh) 2006-02-24 2009-05-06 得克萨斯系统大学评议会 治疗癌症的己糖化合物
JP2009531301A (ja) 2006-02-24 2009-09-03 ボード オブ リージェンツ オブ ザ ユニバーシティ オブ テキサス システム 癌治療のためのヘキソース化合物
JP5885378B2 (ja) 2006-03-22 2016-03-22 ザ スクリプス リサーチ インスティテュート グリコペプチドの調製法
US9149489B2 (en) 2006-04-27 2015-10-06 Board Of Regents, University Of Texas System Inhibitors of glycolysis useful in the treatment of brain tumors
WO2009108926A1 (en) 2008-02-29 2009-09-03 Board Of Regents, The University Of Texas System Inhibitors of glycolysis useful in the treatment of brain tumors
US20100150948A1 (en) 2006-10-24 2010-06-17 Trubion Pharmaceuticals, Inc. Materials and methods for improved immunoglycoproteins
JP5511390B2 (ja) 2007-02-09 2014-06-04 グリコミメティクス， インコーポレイテッド ヘキソースおよびｎ−アセチルヘキソサミンの置換体を有する糖模倣体の使用方法
WO2008131024A1 (en) 2007-04-17 2008-10-30 Board Of Regents, The University Of Texas System Iodo-hexose compounds useful to treat cancer
CN101062939A (zh) 2007-05-17 2007-10-31 北京热景生物技术有限公司 检测肝癌岩藻糖基化高尔基蛋白gp73的装置及试剂盒
KR101658083B1 (ko) 2007-10-19 2016-09-30 시애틀 지네틱스, 인크. 씨디19 결합제 및 그의 용도
US20110003338A1 (en) 2008-03-11 2011-01-06 Robert Bayer Antibodies with enhanced adcc function
CN102076865B (zh) 2008-05-02 2016-03-16 西雅图基因公司 用于制造核心岩藻糖基化降低的抗体和抗体衍生物的方法和组合物
WO2009143078A2 (en) 2008-05-19 2009-11-26 Board Of Regents, The University Of Texas System Methods of treating brain cancer using hexose compounds
WO2009143515A2 (en) 2008-05-23 2009-11-26 University Of Miami Treatment using continuous low dose application of sugar analogs
AU2009268937A1 (en) * 2008-06-16 2010-01-14 Aj Park Compositions for inducing immune responses specific to Globo H and SSEA3 and uses thereof in cancer treatment
EP2411529A4 (en) 2009-03-27 2012-09-19 Zacharon Pharmaceuticals Inc MODULATORS OF BIOSYNTHESIS OF N-BOUND GLYCANS
EP2566876A4 (en) 2010-05-06 2014-01-08 Univ Fraser Simon METHOD AND COMPOUNDS FOR INHIBITING GLYCOSYL TRANSFERASES
US20110288880A1 (en) 2010-05-07 2011-11-24 Patient Care Automation Services, Inc. Targeted health care messaging
MX356671B (es) 2010-08-05 2018-06-08 Seattle Genetics Inc Métodos para inhibir fucosilación de proteína in vivo utilizando análogos de fucosa.
US20120276108A1 (en) 2011-01-11 2012-11-01 Intertech Bio Monosaccharide-based compounds for the treatment of proliferative and inflammatory dermatological diseases
US8979675B2 (en) 2012-04-25 2015-03-17 Nike, Inc. Golf ball core having radial appendages
CA2882725C (en) 2012-08-23 2021-03-09 Regents Of The University Of Minnesota Treatment of sickle cell disease and inflammatory conditions
SG10202005298RA (en) 2015-12-04 2020-07-29 Seattle Genetics Inc Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor

Also Published As

Publication number Publication date
US10342811B2 (en) 2019-07-09
AU2011285490B2 (en) 2016-04-21
AU2016204495A1 (en) 2016-07-21
ES2711622T3 (es) 2019-05-06
JP2020040974A (ja) 2020-03-19
AU2011285490A1 (en) 2013-01-10
EP2608796B1 (en) 2018-11-21
PL2608796T3 (pl) 2019-04-30
US20210260086A1 (en) 2021-08-26
RU2017122482A (ru) 2019-01-30
EP3513794A3 (en) 2019-10-16
SI2608796T1 (sl) 2019-03-29
TR201902439T4 (tr) 2019-03-21
JP5918235B2 (ja) 2016-05-18
CY1121419T1 (el) 2020-05-29
KR101950520B1 (ko) 2019-02-20
JP2017149723A (ja) 2017-08-31
JP6113887B2 (ja) 2017-04-12
MX2013001303A (es) 2014-07-24
ZA201300653B (en) 2014-03-26
EP2608796A4 (en) 2014-06-11
KR20130135240A (ko) 2013-12-10
CN103402525A (zh) 2013-11-20
US20170035790A1 (en) 2017-02-09
IL244019B (en) 2019-09-26
DK2608796T3 (en) 2019-03-18
US20200061091A1 (en) 2020-02-27
JP2013541503A (ja) 2013-11-14
WO2012019165A2 (en) 2012-02-09
IL224487A (en) 2016-07-31
JP2016175909A (ja) 2016-10-06
WO2012019165A3 (en) 2013-08-15
HUE043370T2 (hu) 2019-08-28
RU2625768C2 (ru) 2017-07-18
RU2017122482A3 (es) 2019-01-30
EP2608796A2 (en) 2013-07-03
IL244019A0 (en) 2016-04-21
NZ606250A (en) 2015-04-24
US11033561B2 (en) 2021-06-15
PT2608796T (pt) 2019-02-25
AU2017279653A1 (en) 2018-01-18
CN107007615A (zh) 2017-08-04
RU2013109415A (ru) 2014-09-10
EP3513794A2 (en) 2019-07-24
KR20190022884A (ko) 2019-03-06
CN103402525B (zh) 2017-03-01
JP6622238B2 (ja) 2019-12-18
US20130129784A1 (en) 2013-05-23
CA2803388A1 (en) 2012-02-09
US9504702B2 (en) 2016-11-29
CA2803388C (en) 2019-11-05

Similar Documents

Publication Publication Date Title
MX356671B (es) Métodos para inhibir fucosilación de proteína in vivo utilizando análogos de fucosa.
MX336682B (es) Anticuerpos contra csf-1r humanos y usos de los mismos.
MX347734B (es) Anticuerpos anti-s100a4 y usos aplicaciones terapéuticas.
MX2013013913A (es) Polipeptidos.
TW201129381A (en) Antibodies against human CSF-1R and uses thereof
PH12013502192A1 (en) Antibodies against human angiopoietin 2
MX346500B (es) Metodos y composiciones para inmunoterapia para enfermedad neural.
MX2012007806A (es) Composiciones farmaceuticas para administracion oral de peptidos de insulina.
MX2013008850A (es) Composiciones y metodos para tratar enfermedades cardiovasculares.
MY195289A (en) Anti IL-36R Antibodies
MY178926A (en) Bispecific anti-vegf/anti-ang-2 antibodies
JO3118B1 (ar) تراكيب وطرق لبروتين c5 المتمم يستهدف الأجسام المضادة
MX362039B (es) Anticuerpos anti-il-23.
MX2013000958A (es) Fabricación del inhibidor-inter-alfa (iaip) a partir de plasma.
PH12014502406A1 (en) Anti-il-23p19 antibodies
TN2013000378A1 (en) Anti - sclerostin antibody crystals and formulations thereof
EP3157554A4 (en) Compositions, methods and therapies for administering antigen peptide
SG178596A1 (en) Methods of treatment using anti-oxidized ldl antibodies
MX2013010947A (es) Complejos de galio, composiciones farmacéuticas y métodos de uso.
WO2011150117A3 (en) Enhanced disease resistance by introduction of nh3
TN2011000041A1 (en) Compositions and methods for antibodies targeting complement protein c5
TN2010000463A1 (en) Compositions and methods for preparing and using same

Legal Events

Date Code Title Description
FG Grant or registration